- Home
- ABEO vs NLSP Comparison
ABEO vs NLSP Comparison
Compare ABEO & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABEO
- NLSP
- Stock Information
- Founded
- ABEO 1974
- NLSP 2015
- Country
- ABEO United States
- NLSP Switzerland
- Employees
- ABEO N/A
- NLSP N/A
- Industry
- ABEO Biotechnology: Pharmaceutical Preparations
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- ABEO Health Care
- NLSP Health Care
- Exchange
- ABEO Nasdaq
- NLSP Nasdaq
- Market Cap
- ABEO 256.9M
- NLSP 12.4M
- IPO Year
- ABEO 1980
- NLSP 2021
- Fundamental
- Price
- ABEO $6.00
- NLSP $2.50
- Analyst Decision
- ABEO Strong Buy
- NLSP
- Analyst Count
- ABEO 6
- NLSP 0
- Target Price
- ABEO $18.00
- NLSP N/A
- AVG Volume (30 Days)
- ABEO 1.1M
- NLSP 411.8K
- Earning Date
- ABEO 08-11-2025
- NLSP 07-15-2025
- Dividend Yield
- ABEO N/A
- NLSP N/A
- EPS Growth
- ABEO N/A
- NLSP N/A
- EPS
- ABEO N/A
- NLSP N/A
- Revenue
- ABEO N/A
- NLSP N/A
- Revenue This Year
- ABEO N/A
- NLSP N/A
- Revenue Next Year
- ABEO $323.51
- NLSP N/A
- P/E Ratio
- ABEO N/A
- NLSP N/A
- Revenue Growth
- ABEO N/A
- NLSP N/A
- 52 Week Low
- ABEO $3.93
- NLSP $1.30
- 52 Week High
- ABEO $7.32
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- ABEO 48.03
- NLSP 52.64
- Support Level
- ABEO $5.49
- NLSP $2.16
- Resistance Level
- ABEO $6.11
- NLSP $3.08
- Average True Range (ATR)
- ABEO 0.28
- NLSP 0.24
- MACD
- ABEO -0.04
- NLSP -0.00
- Stochastic Oscillator
- ABEO 47.06
- NLSP 30.21
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.